What Is GLP-1—and Where Does Movement Fit?

Starting a GLP-1 medication can feel like a major turning point. Appetite may change. Food may take up less mental space. The scale may begin to move after years of frustration.

That is meaningful. It is also not the end of the story.

GLP-1–based medications can support weight management and metabolic health, but they do not automatically create a movement routine, maintain every aspect of physical function or know how much capacity you have today. Movement still matters—not as payment for eating and not as a test of willpower, but as one way to support strength, mobility, confidence and everyday life.

The short answer

GLP-1 is a hormone involved in appetite, digestion and blood-sugar regulation. Some medications mimic GLP-1; tirzepatide acts on both GIP and GLP-1 receptors. These treatments can reduce appetite and help people feel full sooner, among other effects.

Movement does a different job. It supports the heart, muscles, bones, balance, mobility and the ability to do ordinary things. Medication and movement are not competitors, and movement does not “prove” that someone is using medication correctly. They are different parts of a broader health plan.

What does GLP-1 do in the body?

After you eat, your digestive system releases hormones that help coordinate what happens next. GLP-1 is one of them. It helps stimulate insulin release when blood glucose is elevated, reduces glucagon in a glucose-dependent way, influences appetite signals and can slow gastric emptying.

Medications such as semaglutide act at the GLP-1 receptor. Tirzepatide acts at both the GIP and GLP-1 receptors, so it is often grouped into the same public conversation even though its mechanism is not identical.

Large randomized trials show why these medications changed obesity care. In STEP 1, adults without diabetes who received semaglutide 2.4 mg alongside lifestyle intervention lost an average of 14.9% of their starting weight over 68 weeks, compared with 2.4% with placebo. In SURMOUNT-1, average weight change over 72 weeks ranged from 15.0% to 20.9% across tirzepatide doses, compared with 3.1% with placebo.

Those are group averages from specific trials—not a forecast for any one person. Response, side effects, access and treatment goals vary. Medication decisions belong with a qualified clinician who knows your health history.

What does the medication not do automatically?

It does not build a routine around your meetings, caregiving, joint limitations or the way your energy changes from day to day.

It does not turn ordinary movement into a habit. It does not know whether ten minutes is realistic today or whether standing exercises feel safer than getting onto the floor. It does not replace strength, balance or mobility practice.

And it does not make exercise a moral obligation. A person who needs rest is not failing treatment. A person who starts with three minutes is not doing “too little.”

This distinction matters because the best movement plan is rarely the most ambitious one on paper. It is the one that can be adjusted, repeated and returned to after a difficult day.

Why movement still matters during a GLP-1 journey

Public-health guidance recommends regular aerobic and muscle-strengthening activity because physical activity benefits cardiovascular health, strength, function, mood and many other outcomes. Those benefits still matter when weight is changing with medication.

Recent expert guidance on GLP-1–based therapy also emphasizes resistance exercise, adequate nutrition and attention to physical function. That does not mean everyone needs a gym program or a rigid weekly target. It means weight alone cannot describe the whole outcome.

Useful questions include:

• Is it easier to stand from a chair?
• Can you carry groceries with more confidence?
• Are short walks becoming more comfortable?
• Can you return to movement after a low-energy day without feeling that the week is ruined?

These are not secondary wins. They are part of living in your body.

There is no universal “GLP-1 workout”

People use different medications, doses and schedules. They begin from different fitness levels and live with different symptoms, injuries and responsibilities. Even the same person may feel different from one week to the next.

That makes a fixed shot-day calendar a poor universal rule. Some people notice a repeating pattern around their injection; others do not. The safest starting point is your actual experience, not an assumption based only on the day of the week.

A more adaptable approach asks:

1. How is your energy today?
2. Are side effects affecting normal activity?
3. How much time is genuinely available?
4. Is there pain, dizziness or another reason to pause?
5. What kind of movement feels accessible—walking, supported standing work, chair-based movement, mobility or rest?

If symptoms are severe, persistent or concerning, movement planning should stop and medical guidance should take priority.

What a realistic movement system can look like

A sustainable system has more than one acceptable day.

On a higher-capacity day, you might complete the plan you expected. On a lower-capacity day, the plan may become shorter, slower or more supported. On a day when rest is the appropriate choice, rest can be part of the system rather than evidence that the system failed.

Progress can come from making movement easier to begin:

• choosing a time that already has space around it
• keeping a short option available
• using a chair or wall for support
• treating walking and strength as complementary, not interchangeable
• adjusting after feedback instead of abandoning the whole plan.

The goal is not to win one perfect week. It is to keep movement available across many imperfect ones.

How Stappn approaches this

Stappn uses the information you report—your injection schedule, energy, side effects, available time, goals, limitations and recent activity—to create or adapt a movement plan.

It does not diagnose symptoms, determine medication dosing or replace your clinician. Its role is narrower: help movement fit the day you actually have.

That may mean a brief supported session, a walking target that reflects your current capacity or a smaller plan when your check-in says today is different. The aim is consistency without pretending every day should look the same.

The takeaway

GLP-1 medication can change appetite and weight-management physiology. Movement supports a different set of needs: strength, function, mobility and the rhythm of daily life.

You do not have to choose between respecting what the medication does and building what it cannot do for you automatically. Start with the day in front of you. Let the plan adapt. Small movement still counts.

This article is for general educational purposes and is not a substitute for medical advice. Medication, dose, side-effect and treatment decisions should be discussed with a qualified healthcare professional.

Sources

1. FDA prescribing information for Wegovy
2. FDA prescribing information for Zepbound
3. STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity
4. SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity
5. WHO Guidelines on Physical Activity and Sedentary Behaviour
6. Nutritional Priorities to Support GLP-1 Therapy for Obesity: Joint Advisory